| 46.07 1.63 (3.67%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 53.8 |
1-year : | 62.84 |
| Resists | First : | 46.06 |
Second : | 53.8 |
| Pivot price | 44 |
|||
| Supports | First : | 42.5 |
Second : | 40.29 |
| MAs | MA(5) : | 44.52 |
MA(20) : | 43.67 |
| MA(100) : | 36.58 |
MA(250) : | 33.59 |
|
| MACD | MACD : | 1.3 |
Signal : | 1.3  |
| %K %D | K(14,3) : | 82.4 |
D(3) : | 73.9 |
| RSI | RSI(14): 72.4 |
|||
| 52-week | High : | 46.06 | Low : | 22.32 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ SBIO ] has closed below upper band by 1.0%. Bollinger Bands are 25.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 46.13 - 46.3 | 46.3 - 46.44 |
| Low: | 43.82 - 44.03 | 44.03 - 44.2 |
| Close: | 45.74 - 46.08 | 46.08 - 46.35 |
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Sat, 08 Nov 2025
(SBIO) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Tue, 07 Oct 2025
5 Small-cap Biotech ETFs to Watch in 2025 - Investing News Network
Thu, 11 Sep 2025
3 Stocks Driving Biotech ETF SBIO’s Appeal - ETF Trends
Fri, 29 Aug 2025
This Underrated Tech ETF Is Spiking Amid Rate Cut Hype - ETF Trends
Fri, 15 Aug 2025
Is Biotech the Right Tech ETF Move Right Now? SBIO Argues Yes - ETF Trends
Wed, 16 Jul 2025
611,400 Shares in ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Acquired by DAVENPORT & Co LLC - 富途牛牛
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
AMEX
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Asset Management
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|